Literature DB >> 17948889

R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.

Anton Reiner1, Nobel Del Mar, Yun-Ping Deng, Christopher A Meade, Zhiqiang Sun, Daniel Goldowitz.   

Abstract

The R6/2 mouse possesses mutant exon 1 of human Hdh, and R6/2 mice with 150 CAG repeats show neurological abnormalities by 10 weeks and die by 15 weeks. Few brain abnormalities, however, are evident at death, other than widespread ubiquitinated neuronal intranuclear inclusions (NIIs). We constructed R6/2t+/t- <--> wildtype (WT) chimeric mice to prolong survival of R6/2 cells and determine if neuronal death and/or neuronal injury become evident with longer survival. ROSA26 mice (which bear a lacZ transgene) were used as WT to distinguish between R6/2 and WT neurons. Chimeric mice consisting partly of R6/2 cells lived longer than pure R6/2 mice (up to 10 months), with the survival proportional to the R6/2 contribution. Genotypically R6/2 cells formed NIIs in the chimeras, and these NIIs grew only slightly larger than in 12-week pure R6/2 mice, even after 10 months. Additionally, neuropil aggregates formed near R6/2 neurons in chimeric mice older than 15 weeks. Thus, R6/2 neurons could survive well beyond 15 weeks in chimeras. Moreover, little neuronal degeneration was evident in either cortex or striatum by routine histological stains. Nonetheless, striatal shrinkage and ventricular enlargement occurred, and striatal projection neuron markers characteristically reduced in Huntington's disease were diminished. Consistent with such abnormalities, cortex and striatum in chimeras showed increased astrocytic glial fibrillary acidic protein. These results suggest that while cortical and striatal neurons can survive nearly a year with nuclear and extranuclear aggregates of mutant huntingtin, such lengthy survival does reveal cortical and striatal abnormality brought on by the truncated mutant protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948889     DOI: 10.1002/cne.21515

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  18 in total

Review 1.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

Review 2.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

3.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

4.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

Review 5.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

6.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

Review 7.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

8.  A Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice.

Authors:  Natalie H Guley; Joshua T Rogers; Nobel A Del Mar; Yunping Deng; Rafiqul M Islam; Lauren D'Surney; Jessica Ferrell; Bowei Deng; Jessica Hines-Beard; Wei Bu; Huiling Ren; Andrea J Elberger; Jeffrey G Marchetta; Tonia S Rex; Marcia G Honig; Anton Reiner
Journal:  J Neurotrauma       Date:  2015-12-17       Impact factor: 5.269

9.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

10.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.